FDA grants acceptance to file and Priority Review for Beleodaq™ (belinostat) NDA in PTCL
06 févr. 2014 07h00 HE
|
Topotarget
To NASDAQ OMX Copenhagen A/S
Announcement no. 02-14 / Copenhagen, February 6, 2014
Topotarget A/S announces that the FDA has granted acceptance to file and Priority Review for the BeleodaqTM NDA...
Topotarget announces interim report for the period January 1 - December 31, 2013
30 janv. 2014 02h01 HE
|
Topotarget
To NASDAQ OMX Copenhagen A/S
Announcement no. 01-14 / Copenhagen, January 30, 2014
Topotarget announces that the board of directors has reviewed and approved the company’s interim report for the...
Topotarget offentliggør delsårsrapport for perioden 1. januar - 31. december 2013
30 janv. 2014 02h01 HE
|
Topotarget
Til NASDAQ OMX Copenhagen A/S
Meddelelse nr. 01-14 / København, 30. januar 2014
Topotarget meddeler, at bestyrelsen i dag har behandlet og godkendt selskabets delårsrapport for perioden 1. januar...
Telekonference vedr. delårsrapport for perioden 1. januar – 31. december 2013
23 janv. 2014 08h35 HE
|
Topotarget
Til NASDAQ OMX Copenhagen A/S
Investor Nyhed nr. 01-14 / København, 23. januar 2014
Topotarget afholder telekonference vedr. selskabets delårsrapport for perioden 1. januar – 31. december 2013...
Teleconference regarding interim report for the period January 1 – December 31, 2013
23 janv. 2014 08h35 HE
|
Topotarget
To NASDAQ OMX Copenhagen A/S
Investor News no. 01-14 / Copenhagen, January 23, 2014
Topotarget will host a teleconference regarding the company’s interim report for the period January 1 –...
New Drug Application for belinostat in relapsed or refractory PTCL submitted to the FDA in the USA
10 déc. 2013 07h02 HE
|
Topotarget
To NASDAQ OMX Copenhagen A/S
Announcement no. 28-13 / Copenhagen, December 10, 2013
Topotarget announces the submission of a New Drug Application (NDA) for belinostat for the treatment of...
Registreringsansøgning for belinostat til behandling af recidiverende eller resistent PTCL indsendt til FDA i USA
10 déc. 2013 07h02 HE
|
Topotarget
Til NASDAQ OMX Copenhagen A/S
Meddelelse nr. 28-13 / København, 10. december 2013
Topotarget meddeler hermed, at der er indsendt en registreringsansøgning (NDA) til de amerikanske...
Allowance of key belinostat patent in Europe
21 nov. 2013 04h40 HE
|
Topotarget
To NASDAQ OMX Copenhagen A/S
Announcement no. 27-13 / Copenhagen, November 21, 2013
The European patent covering Composition of Matter for belinostat has been granted. The patent will protect...
Topotarget får tildelt vigtigt patent for belinostat i Europa
21 nov. 2013 04h40 HE
|
Topotarget
Til NASDAQ OMX Copenhagen A/S
Meddelelse nr. 27-13 / København, 21. november 2013
Der er tildelt europæisk patent, som dækker stofkrav for belinostat. Patentet vil beskytte belinostat mod...
Endelige resultater fra CLN-14-studiet i bløddelssarkom
20 nov. 2013 07h45 HE
|
Topotarget
Til NASDAQ OMX Copenhagen A/S
Meddelelse nr. 26-13 / København, 20. november 2013
Topotarget offentliggør de endelige resultater fra det første stadie af fase II-delen af det kliniske fase...